查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1939518

EVA輸液袋市場按腔室類型、應用和最終用戶分類，全球預測（2026-2032）

EVA Infusion Bags Market by Chamber Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 EVA 輸液袋市值為 2.6455 億美元，預計到 2026 年將成長至 2.9402 億美元，到 2032 年將達到 5.1243 億美元，複合年成長率為 9.90%。

主要市場統計數據
基準年 2025 2.6455億美元
預計年份：2026年 2.9402億美元
預測年份：2032年 5.1243億美元
複合年成長率 (%) 9.90%

對EVA輸液袋的權威介紹為推動臨床實踐、法規環境和供應鏈趨勢中的選擇和創新提供了框架。

EVA輸液袋已成為現代腸外營養治療中日益重要的組成部分，它結合了材料科學的進步以及安全性、相容性和供應鏈穩定性等實際考慮。隨著臨床醫生和採購團隊尋求在化學惰性、易操作性和無菌性之間取得平衡，基於EVA的系統因其材料穩定性、靈活的生產過程以及與替代聚合物相比更低的析出物含量而持續受到關注。這些特性不僅在急診醫院環境中至關重要，在門診和家庭輸液場景中也同樣重要，因為易操作性和儲存穩定性會影響臨床應用。

本文簡要檢驗了技術創新、監管重點和不斷變化的醫療服務模式如何重新定義輸液袋產品策略和採購。

由於技術創新、監管趨嚴以及醫療模式重組，輸液輸送系統格局正在改變。在技​​術方面，材料科學的進步推動了EVA配方的發展，使其具有更優異的阻隔性能和更廣泛的配方相容性，迫使製造商重新評估產品系列和生產投資。同時，供應商正在採用先進的滅菌方法和精密的品質分析技術，這些措施共同提高了產品合格標準，並降低了批間差異。

分析2025年關稅對整個靜脈輸液袋價值鏈的策略性地域多角化、多元化和供應鏈韌性措施的影響

影響跨境貿易的政策決策直接影響醫療設備組件（包括輸液袋）的供應鏈連續性、成本結構和採購選擇。 2025年關稅的實施改變了整個採購行業的成本核算方式，並引發了製造商和經銷商的多項即時應變措施。一些供應商加快了區域產品認證和本地化進程，以降低關稅波動帶來的風險。另一些供應商則重新審視了供應商契約，尋求簽訂長期協議或將採購來源多元化，轉向受影響貿易走廊以外的其他供應商。這些措施降低了對單一供應來源的依賴，提高了供應鏈的韌性，但也帶來了過渡成本，並增加了供應商關係管理的複雜性。

透過綜合分析，將腔室設計、臨床環境、病患人口統計特徵、體積細分和通路等因素納入考量，進而解釋產品選擇因素。

要了解產品性能和商業性動態，需要從產品細分的觀點，考慮設計、使用環境、患者群、包裝容量和分銷管道。腔室配置是關鍵的差異化因素。單腔室設計優先考慮簡潔性和與標準解決方案的廣泛相容性，而多腔室設計，包括雙腔室、三腔室、四腔室或更多腔室配置，則能夠實現組合藥物配製、成分延遲混合或在單一包裝內給藥多種藥物。因此，當臨床通訊協定需要精確配製或分離以確保穩定性時，多腔室設計是更好選擇。

區域洞察：美洲、歐洲、中東和非洲以及亞太地區之間的差異將如何影響監管策略、採購重點和分銷模式

區域因素對全球輸液袋市場的供應策略、監管應對措施和商業性重點有顯著影響。在美洲地區，採購決策主要取決於供應商的可靠性、是否符合當地醫療設備法規以及與醫院系統的整合程度。急診護理需求仍然是核心促進因素，同時，支持門診輸液計畫以減輕住院患者的負擔也日益受到重視。服務該地區的製造商通常會投資建造本地品質系統和物流中心，以滿足嚴格的服務水準要求並快速回應醫院網路的競標。

對競爭定位進行策略性評估，重點在於技術差異化、服務整合、通路夥伴關係和永續性作為關​​鍵優勢。

輸液袋領域的競爭格局呈現出成熟企業與專注於材料科學和品質體系服務能力的敏捷型新興企業的並存態勢。領先的供應商憑藉檢驗的材料平台、可靠的萃取物和浸出物數據以及可擴展的生產基礎設施脫穎而出，從而能夠快速響應臨床需求。對自動化和品質分析的策略性投資使製造商能夠降低產品變異性並加強監管申報，從而為那些能夠持續證明產品品質的公司創造競爭優勢。

為供應商和買家提供切實可行的、影響深遠的建議，以提升材料合格、社區韌性、門診病人支援計畫和永續性合規性。

產業領導者可以採取以下幾項切實可行的措施來增強韌性、加快產品上市速度並滿足不斷變化的臨床需求。首先，優先考慮嚴格的材料合格流程，將先進的萃取物和萃取物測試與實際應用相容性測試相結合。這有助於減少監管摩擦，並增強臨床醫生和採購相關人員的信心。其次，投資模組化製造和區域供應中心，以降低貿易中斷的風險，同時保持柔軟性，以便快速回應需求波動。第三，為門診和家庭輸液患者開發支援項目，包括簡化的配藥指南、給藥輔助工具和遠距訓練模組，以提高非急性環境下的安全性和應用率。

我們採用透明嚴謹的調查方法，結合專家訪談、監管分析和技術文獻綜述，為我們的實用結論和建議提供了支持。

本分析整合了對臨床採購主管、產品開發專業人員和分銷合作夥伴的訪談，並系統性回顧了與輸液容器和聚合物材料相關的監管指南和技術文獻。主要資料收集著重於決策者在急診、門診和居家照護環境中的優先事項（產品處理偏好、文件需求、採購標準等）。次要分析著重於已發布的法規結構、材料科學出版物以及關於醫療服務模式和供應鏈中斷的趨勢報告。

針對輸液袋生態系統中尋求永續競爭優勢的利益相關人員，本文總結了技術、商業和營運方面的優先事項，並提出了簡潔扼要的結論。

EVA輸液袋在材料創新、臨床需求和供應鏈現實的交匯點佔據著策略性地位。日益嚴格的監管要求、向門診和家庭輸液的轉變以及貿易中斷等因素，都要求採用一種融合技術合格、供應鏈韌性和以客戶為中心的服務的綜合方法。能夠展現嚴格的材料特性分析、可擴展的品質系統和靈活的物流能力的製造商，將更有能力滿足不同醫療機構中臨床醫生的期望和採購標準。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • CXO觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新たな商機
  • 次世代經營模式
  • 産業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • ポーターの五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESGとサステナビリティ分析
  • ディスラプションとリスクシナリオ
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按腔室類型分類的EVA輸液袋市場

  • マルチチャンバー
    • 雙腔體
    • クアッドチャンバー以上
    • 三腔體
  • 單室

9. 按應用分類的EVA輸液袋市場

  • 成人
  • 新生
  • 兒童

第10章 EVA輸液袋市場（以最終用戶分類）

  • 門診治療
  • 診所
  • 居家醫療
  • 醫院

第11章 EVA輸液袋市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 EVA輸液袋市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 EVA輸液袋市場（按國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

14. 美國EVA輸液袋市場

第15章：中國EVA輸液袋市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Hemedis GmbH
  • ICU Medical, Inc.
  • Medline Industries, LP
  • Nanjing Tianxin Pharmaceutical Sci & Tech Development Co., Ltd.
  • Nipro Corporation
  • Poly Medicure Limited
  • Terumo Corporation
  • Valmed SRL
  • Weigao Group Medical Polymer Co., Ltd.
Product Code: MRR-9A6A6F2977F5

The EVA Infusion Bags Market was valued at USD 264.55 million in 2025 and is projected to grow to USD 294.02 million in 2026, with a CAGR of 9.90%, reaching USD 512.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 264.55 million
Estimated Year [2026] USD 294.02 million
Forecast Year [2032] USD 512.43 million
CAGR (%) 9.90%

An authoritative introduction that frames EVA infusion bags within clinical, regulatory, and supply chain dynamics driving selection and innovation

EVA infusion bags are an increasingly prominent component of contemporary parenteral therapy, combining material science advances with practical considerations around safety, compatibility, and supply chain resilience. As clinicians and procurement teams seek solutions that balance chemical inertness, ease of handling, and sterile integrity, EVA-based systems continue to attract attention for their material consistency, flexible manufacturing pathways, and potential to reduce leachables relative to alternative polymers. These attributes matter not only in acute care hospital settings but also across ambulatory and home infusion scenarios where handling ease and storage stability influence clinical adoption.

Concurrently, industry stakeholders are navigating converging pressures from regulatory scrutiny, sustainability commitments, and changing care delivery models. Regulators have sharpened expectations for container-closure system testing and extractables and leachables characterization, prompting manufacturers to refine material selection and qualification protocols. Meanwhile, the shift toward outpatient infusion and home healthcare increases demand for packaging formats that are robust, lightweight, and user-friendly, while distributors and pharmacies prioritize predictable shelf life and cold-chain compatibility where relevant. Taken together, these dynamics set the context for product innovation, procurement strategy evolution, and competitive differentiation across the infusion bag landscape.

A concise examination of how technological advances, regulatory focus, and shifting care delivery models are redefining infusion bag product strategy and procurement

The landscape for infusion delivery systems is undergoing transformative shifts driven by technology, regulatory emphasis, and care model reconfiguration. On the technology front, material science improvements have produced EVA formulations that exhibit improved barrier properties and compatibility with a wider range of formulations, prompting manufacturers to reassess product portfolios and manufacturing investments. In parallel, suppliers are adopting advanced sterilization approaches and enhanced quality analytics, which together raise the baseline for product qualification and reduce variability across batches.

Regulatory agencies are placing greater emphasis on container-closure integrity and the rigorous assessment of extractables and leachables, which changes the development timelines and documentation requirements for new product introductions. These regulatory shifts incentivize firms to invest in standardized testing frameworks and more transparent data packages, promoting long-term trust with healthcare purchasers. At the same time, the care delivery environment is moving toward decentralized models; outpatient infusion clinics, home healthcare programs, and ambulatory services are expanding, and they require products that simplify handling, reduce preparation time, and support safe administration by non-specialist caregivers. Collectively, these shifts are reshaping supplier strategies, accelerating consolidation in some value chain segments, and opening opportunities for device differentiation through both material and service propositions.

An informed analysis of how recent tariff measures in 2025 triggered strategic regionalization, diversification, and supply chain resilience measures across the infusion bag value chain

Policy decisions that affect cross-border trade have direct implications for supply chain continuity, cost structures, and sourcing choices for medical device components, including infusion bags. The imposition of tariffs in 2025 altered cost calculus across procurement teams and prompted several immediate responses from manufacturers and distributors. Some suppliers accelerated regional qualification and localization efforts to reduce exposure to tariff volatility, while others revisited supplier agreements, seeking longer-term contracts or diversification to alternative suppliers outside affected trade corridors. These actions reduced single-source dependencies and improved resilience, but they also introduced transition costs and complexity into supplier relationship management.

Importantly, healthcare purchasers responded by updating total-cost evaluations to include tariff-driven landed cost fluctuations and by prioritizing suppliers with transparent sourcing and distribution footprints. Regulatory compliance and product equivalency remained primary selection criteria, yet procurement teams increasingly valued robust logistics assurances, predictable lead times, and secondary sourcing options. To mitigate future trade-related disruptions, several manufacturers expanded inventory buffers and negotiated forward-looking supply agreements, balancing risk tolerance against working capital impacts. Overall, the 2025 tariff environment accelerated strategic decisions around regionalization, supplier diversification, and operational contingency planning across the infusion bag ecosystem.

A comprehensive segmentation insight that integrates chamber design, care settings, patient application, capacity tiers, and distribution pathways to explain product selection drivers

Understanding product performance and commercial dynamics requires a segmentation lens that reflects design, use setting, patient population, packaging capacity, and distribution pathways. Chamber architecture is a central differentiator: single chamber designs prioritize simplicity and broad compatibility for standard fluids, while multi chamber formats-spanning dual, triple, and quad or higher chamber configurations-enable co-formulation, delayed mixing of components, or multi-drug administration in a single package, and thus are selected when clinical protocols demand precision or stability-preserving separation.

End-user context influences product selection and handling requirements. Hospitals typically demand high-volume formats and standardized compatibility with infusion devices, ambulatory care and clinic settings balance portability with sterility assurances, and home healthcare prioritizes intuitive design, clear labeling, and low preparation burden to support non-professional caregivers. Application-driven differences also shape requirements; adult formulations often necessitate larger capacities and robust compatibility testing, while neonatal and pediatric applications emphasize low dead space, precise dosing, and materials that minimize extractables relative to vulnerable patient populations. Capacity considerations-ranging from small-volume options up to 100 ml through mid-range 101-500 ml and larger greater-than-500 ml formats-determine packaging footprint, dosing strategies, and storage conditions. Finally, distribution pathways influence commercial dynamics: distributors and hospital pharmacies manage bulk procurement and inventory rotation, retail and online pharmacies prioritize point-of-care availability and consumer-facing labeling, and each channel imposes distinct regulatory and logistical requirements that manufacturers must address through packaging, documentation, and service-level commitments.

A regional insight that maps how Americas, Europe Middle East & Africa, and Asia-Pacific differences shape regulatory strategy, procurement priorities, and distribution models

Regional considerations materially influence supply strategies, regulatory alignment, and commercial priorities across the global infusion bag landscape. In the Americas, procurement decision-making emphasizes supplier reliability, compliance with local device regulations, and integration with hospital systems; acute care demand remains a core driver, and there is growing interest in support for outpatient infusion programs that reduce inpatient burdens. Manufacturers serving this region often invest in local quality systems and logistics hubs to meet tight service-level expectations and to respond quickly to hospital network tenders.

Europe, Middle East & Africa presents a heterogeneous regulatory and procurement environment that rewards flexible supply models and comprehensive technical dossiers. Diverse reimbursement models and national regulatory regimes require adaptable market access strategies and robust clinical evidence packages. The region also shows a rising appetite for sustainability considerations in packaging and supply operations, which influences supplier selection. In Asia-Pacific, rapid expansion of healthcare infrastructure, increased capacity in hospital networks, and growth in home healthcare services create demand for a wide range of capacities and chamber formats. Producers targeting this region often combine competitive manufacturing economics with investments in local regulatory support and distribution partnerships to accelerate adoption. Across all regions, alignment between product attributes and local care models, combined with transparent supply assurances, remains fundamental to commercial success.

A strategic review of competitive positioning that highlights technical differentiation, service integration, channel partnerships, and sustainability as key advantages

Competitive dynamics in the infusion bag sector reflect a mix of legacy incumbents and agile innovators that emphasize material science, quality systems, and service capabilities. Leading suppliers differentiate through validated material platforms, robust extractables and leachables data, and scalable manufacturing footprints that support rapid response to clinical demand. Strategic investments in automation and quality analytics enable manufacturers to reduce variability and strengthen regulatory submissions, creating a competitive moat for those firms that can consistently demonstrate product integrity.

Other firms compete by focusing on end-to-end service offerings, providing sterile filling, customized porting or connector options, and integrated traceability that supports hospital inventory management. Partnerships between device producers and specialty distributors have widened market reach, allowing smaller manufacturers to access large purchasing networks and complex channel requirements. Additionally, companies that prioritize sustainability-through reduced packaging waste, recyclable components, or energy-efficient manufacturing-are beginning to gain preference among healthcare systems that incorporate environmental criteria into procurement. Taken together, these strategic postures-technical differentiation, service integration, channel partnerships, and sustainability leadership-define the competitive contours and create multiple pathways to commercial advantage.

Practical and high-impact recommendations for suppliers and purchasers to enhance material qualification, regional resilience, outpatient support programs, and sustainability alignment

Industry leaders can take several pragmatic actions to strengthen resilience, accelerate product adoption, and meet evolving clinical requirements. First, prioritize a rigorous material qualification pathway that couples advanced extractables and leachables testing with real-world compatibility studies; this reduces regulatory friction and increases confidence among clinician and procurement stakeholders. Second, invest in modular manufacturing and regional supply hubs to limit exposure to trade disruptions while preserving flexibility for rapid scale-up in response to demand shifts. Third, develop targeted support programs for outpatient and home infusion customers, including simplified preparation guides, dosing aids, and remote training modules to improve safety and adoption in non-acute settings.

Moreover, align commercial proposals with sustainability initiatives by optimizing packaging and exploring recyclable or lower-impact materials, thereby meeting growing institutional priorities. Strengthen distribution relationships through clear service-level agreements and digital traceability to enhance inventory visibility and reduce stockouts. Finally, embed flexible contracting options and contingency clauses that permit rapid supplier substitution or volume reallocation, balancing operational resilience with financial discipline. These combined moves will help manufacturers and distributors navigate current uncertainties while positioning for longer-term growth in diversified care settings.

A transparent and rigorous methodology combining expert interviews, regulatory analysis, and technical literature review to underpin practical conclusions and recommendations

This analysis synthesizes primary interviews with clinical procurement leaders, product development specialists, and distribution partners, combined with a structured review of regulatory guidance and technical literature relevant to infusion containers and polymeric materials. Primary data collection emphasized decision-maker priorities across acute, ambulatory, and home care settings, including product handling preferences, documentation needs, and procurement criteria. Secondary analysis focused on publicly available regulatory frameworks, material science publications, and trend reporting related to healthcare delivery models and supply chain disruptions.

The approach triangulated qualitative insights from subject matter experts with document-based evidence to ensure that recommendations are grounded in practice and regulation. Emphasis was placed on cross-validating claims about material performance and handling with practitioners who evaluate these products daily. Limitations include variability in national regulatory interpretations and the ongoing evolution of decentralized care programs, which require continuous monitoring. To mitigate these limits, the methodology incorporated sensitivity checks and scenario-based discussion to reflect a range of plausible operational responses and strategic choices.

A concise conclusion that synthesizes technical, commercial, and operational priorities for stakeholders seeking durable advantage in the infusion bag ecosystem

EVA infusion bags occupy a strategic position at the intersection of material innovation, clinical needs, and supply chain realities. The confluence of stricter regulatory expectations, shifts toward outpatient and home-based infusion, and trade-driven disruptions necessitates an integrated approach that blends technical qualification with supply resilience and customer-centric services. Manufacturers that can demonstrate rigorous material characterization, scalable quality systems, and responsive logistics will be best positioned to meet clinician expectations and procurement thresholds across diverse care settings.

Equally, purchasers and healthcare organizations should emphasize supplier transparency, multi-source strategies, and alignment with sustainability commitments when updating procurement frameworks. The evolving landscape creates opportunities for differentiation through modular product design, targeted channel strategies, and enhanced post-market support that together increase adoption and patient safety. In sum, the sector's immediate priorities involve strengthening technical validation, diversifying supply footprints, and elevating service models to match the demands of modern care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. EVA Infusion Bags Market, by Chamber Type

  • 8.1. Multi Chamber
    • 8.1.1. Dual Chamber
    • 8.1.2. Quad Chamber And Above
    • 8.1.3. Triple Chamber
  • 8.2. Single Chamber

9. EVA Infusion Bags Market, by Application

  • 9.1. Adult
  • 9.2. Neonatal
  • 9.3. Pediatric

10. EVA Infusion Bags Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Clinic
  • 10.3. Home Healthcare
  • 10.4. Hospital

11. EVA Infusion Bags Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. EVA Infusion Bags Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. EVA Infusion Bags Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States EVA Infusion Bags Market

15. China EVA Infusion Bags Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. B. Braun Melsungen AG
  • 16.6. Baxter International Inc.
  • 16.7. Fresenius Kabi AG
  • 16.8. Hemedis GmbH
  • 16.9. ICU Medical, Inc.
  • 16.10. Medline Industries, LP
  • 16.11. Nanjing Tianxin Pharmaceutical Sci & Tech Development Co., Ltd.
  • 16.12. Nipro Corporation
  • 16.13. Poly Medicure Limited
  • 16.14. Terumo Corporation
  • 16.15. Valmed S.R.L.
  • 16.16. Weigao Group Medical Polymer Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EVA INFUSION BAGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EVA INFUSION BAGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY DUAL CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY QUAD CHAMBER AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY TRIPLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY SINGLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EVA INFUSION BAGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA EVA INFUSION BAGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA EVA INFUSION BAGS MARKET SIZE, BY CHAMBER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA EVA INFUSION BAGS MARKET SIZE, BY MULTI CHAMBER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA EVA INFUSION BAGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA EVA INFUSION BAGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)